This site is intended for Healthcare Professionals only.

Esperion Therapeutics’ ‘bempedoic acid’ shows potential to reduce cardiac illnesses, reveals GlobalData


Share post:

Esperion Therapeutics’ non-statin therapy “bempedoic acid” has shown modest results in reducing the risk of major cardiovascular events in statin-intolerant patients in the cholesterol lowering via bempedoic acid, an ACL-inhibiting regimen (CLEAR Outcomes) trial, revealed GlobalData, a leading data and analytics company.

As a result, there is substantial room for improvement in this space as a potential approval is expected in Australia in near-term based on these results, said GlobalData.

According to GlobalData’s Pharmaceutical Intelligence Center, the total number of diagnosed prevalent cases of dyslipidemia in Australia is expected to increase at a compound annual growth rate of approximately 1.2% from 5.2 million in 2022 to 5.4 million in 2025.

Neha Myneni, Pharma Analyst at GlobalData, comments: “Bempedoic acid joins several statin alternatives that have shown the potential to reduce cardiac illnesses. However, with not much significant improvement in the outcomes, there exists a clear room for improvement for non-statin therapies in this space.”

Bempedoic acid is the sixth class of cholesterol-lowering drugs (other than cholesteryl-ester transfer protein isoform (CETPi) inhibitors), that has demonstrated the potential to reduce heart attacks and strokes. Other class of therapies with similar potential currently marketed in Australia include statins, bile acid resins, niacin, ezetimibe, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (alirocumab, evolocumab, and inclisiran).

CETPi inhibitors are example of a failed class of therapy for statin-intolerant patients. Till date, four CETPi inhibitors (Pfizer’s torcetrapib; Merck’s anacetrapib; Roche’s dalcetrapib; and Lilly’s evacetrapib) reached Phase III cardiovascular outcome trials. However, further development of all these molecules was discontinued due to their insufficient cardiovascular benefit for regular use.

Myneni concludes: “With a potential to address about 100,000–500,000 statin-intolerant patients in Australia, bempedoic acid, however, may not be considered an alternate to statin therapy at this juncture with only moderate improvement in LDL lowering efficacy and reduction in cardiovascular risk. Further trials comparing the efficacy of bempedoic acid head-on with statins or other established therapies in future could prove its efficacy in LDL treatment.”


Please enter your comment!
Please enter your name here

Current Issue March 2024

Related articles

RPS joins efforts to boost children’s health in Wales

A group of 20 royal colleges and professional bodies unite to elevate the profile of child health in...

SSPs reactivated for clarithromycin amid surging whooping cough cases

The UK Health Security Agency (UKHSA) has confirmed 2,793 cases of whooping in the first quarter of 2024,...

Insect bites and stings surge: Searches for NHS advice triple

Visit your local pharmacy for advice and treatment of common health conditions, including infected insect bites Insect bites...

RPS Fellowship May 2024 list announced: Benjamin Hannan shines as the youngest Scottish fellow

Hannan joins 783 diverse RPS Fellowship members alongside other new 19 members announced  Benjamin Hannan, director of reform and...